Synthesis and Biological Evaluation of Novel Folic Acid Receptor-Targeted, β-Cyclodextrin-Based Drug Complexes for Cancer Treatment

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Yin, Juan Juan ^a   Sharma, Sonali ^a   Shumyak, Stepan P ^a   Wang, Zhi Xin ^a   Zhou, Zhi Wei ^a   Zhang, Yangde ^b   Guo, Peixuan ^c   Li, Chen Zhong ^d   Kanwar, Jagat R ^e   Yang, Tianxin ^f   Mohapatra, Shyam S ^g   Liu, Wanqing ^h   Duan, Wei ^e   Wang, Jian Cheng ⁱ   Li, Qi ^j   Zhang, Xueji ^k   Tan, Jun ^f,g   Jia, Lee ^l   Liang, Jun ^a   Wei, Ming Q ^m   Li, Xiaotian ⁿ   Zhou, Shu Feng ^a   more..

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c University of Kentucky   (United States)

^d The Department of Electrical and Computer Engineering   (United States)

^e DEAKIN UNIVERSITY   (Australia)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g UNIVERSITY OF SOUTH FLORIDA   (United States)

^h PURDUE UNIVERSITY   (United States)

ⁱ PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^j SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^k UNIVERSITY OF SCIENCE AND TECHNOLOGY BEIJING   (China)

^l FUZHOU UNIVERSITY   (China)

^m GRIFFITH UNIVERSITY   (Australia)

ⁿ FUDAN UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADAMANTANE; BETA CYCLODEXTRIN; BINDING PROTEIN; DOXORUBICIN; FOLATE RECEPTOR; FOLIC ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HEDGEHOG INTERACTING PROTEIN; NANOPARTICLE; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG UPTAKE; ENDOCYTOSIS; ENZYME ACTIVITY; FIBROBLAST; HEART MUSCLE CELL; HUMAN; HUMAN CELL; HYDROPHILICITY; IC 50; IN VITRO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; PARTICLE SIZE; PROTEIN DOMAIN; SUSTAINED DRUG RELEASE; SYNTHESIS; TUMOR CELL;

AMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; BETA-CYCLODEXTRINS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CHEMISTRY TECHNIQUES, SYNTHETIC; DOXORUBICIN; DRUG CARRIERS; FIBROBLASTS; FOLIC ACID; FOLIC ACID TRANSPORTERS; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; INTRACELLULAR SPACE; MICE; MOLECULAR DOCKING SIMULATION; MYOCYTES, CARDIAC; PARTICLE SIZE; PROTEIN CONFORMATION; REACTIVE OXYGEN SPECIES;

ERINACEIDAE;

EID: 84877068650     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062289     Document Type: Article

References (38)

1. Thun MJ, DeLancey JO, (2010) Center MM, Jemal A, Ward EM (2010) The global burden of cancer: priorities for prevention. Carcinogenesis 31: 100-110.
2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, et al. (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
3. Gatenby RA, (2009) A change of strategy in the war on cancer. Nature 459: 508-509.
4. Chabner BA, Roberts TG Jr, (2005) Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer 5: 65-72.
5. Cotter TG, (2009) Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 9: 501-507.
6. Yague E, Raguz S, (2005) Drug resistance in cancer. Br J Cancer 93: 973-976.
7. Petros RA, DeSimone JM, (2010) Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov 9: 615-627.
8. Muro S, (2012) Challenges in design and characterization of ligand-targeted drug delivery systems. J Control Release 164: 125-137.
9. Lammers T, Kiessling F, Hennink WE, Storm G, (2012) Drug targeting to tumors: principles, pitfalls and (pre-) clinical progress. J Control Release 161: 175-187.
10. Wang AZ, Langer R, Farokhzad OC, (2012) Nanoparticle delivery of cancer drugs. Annu Rev Med 63: 185-198.
11. Kizek R, Adam V, Hrabeta J, Eckschlager T, Smutny S, et al. (2012) Anthracyclines and ellipticines as DNA-damaging anticancer drugs: recent advances. Pharmacol Ther 133: 26-39.
12. Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, et al. (2012) Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol 52: 1213-1225.
13. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, (2004) Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56: 185-229.
14. Dickey JS, Rao VA, (2012) Current and proposed biomarkers of anthracycline cardiotoxicity in cancer: emerging opportunities in oxidative damage and autophagy. Curr Mol Med 12: 763-771.
15. Menna P, Paz OG, Chello M, Covino E, Salvatorelli E, et al. (2012) Anthracycline cardiotoxicity. Expert Opin Drug Saf 11Suppl 1: S21-36.
16. Salas C, Perez-Vera P, Frias S, (2011) Genetic abnormalities in leukemia secondary to treatment in patients with Hodgkin's disease. Rev Invest Clin 63: 53-63.
17. Mo SL, Liu WF, Li CG, Zhou ZW, Luo HB, et al. (2012) Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. Curr Pharm Biotechnol 13: 1640-1704.
18. Mo SL, Liu WF, Chen Y, Luo HB, Sun LB, et al. (2012) Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap). Comb Chem High Throughput Screen 15: 36-80.
19. Bishop B, Aricescu AR, Harlos K, O'Callaghan CA, Jones EY, et al. (2009) Structural insights into hedgehog ligand sequestration by the human hedgehog-interacting protein HHIP. Nat Struct Mol Biol 16: 698-703.
20. Roy PP, Roy K, (2010) Pharmacophore mapping, molecular docking and QSAR studies of structurally diverse compounds as CYP2B6 inhibitors. Mol Simul 36: 887-905.
21. Wu G, Robertson DH, Brooks CL 3rd, Vieth M, (2003) Detailed analysis of grid-based molecular docking: A case study of CDOCKER-A CHARMm-based MD docking algorithm. J Comput Chem 24: 1549-1562.
22. Eruslanov E, Kusmartsev S, (2010) Identification of ROS using oxidized DCFDA and flow-cytometry. Methods Mol Biol 594: 57-72.
23. Wang H, Joseph JA, (1999) Quantifying cellular oxidative stress by dichlorofluorescein assay using microplate reader. Free Radic Biol Med 27: 612-616.
24. Beutler E, Duron O, Kelly BM, (1963) Improved method for the determination of blood glutathione. J Lab Clin Med 61: 882-888.
25. Petter RC, Salek JS, Sikorski CT, Kumaravel G, Lin FT, (1990) Cooperative binding by aggregated mono-6-(alkylamino)-β-cyclodextrins. J Am Chem Soc 112: 3860-3868.
26. Crider KS, Yang TP, Berry RJ, Bailey LB, (2012) Folate and DNA methylation: a review of molecular mechanisms and the evidence for folate's role. Adv Nutr 3: 21-38.
27. Sabharanjak S, Mayor S, (2004) Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 56: 1099-1109.
28. Hilgenbrink AR, Low PS, (2005) Folate receptor-mediated drug targeting: from therapeutics to diagnostics. J Pharm Sci 94: 2135-2146.
29. Zhao X, Li H, Lee RJ, (2008) Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 5: 309-319.
30. Weitman SD, Lark RH, Coney LR, Fort DW, Frasca V, et al. (1992) Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res 52: 3396-3401.
31. Davis ME, Brewster ME, (2004) Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov 3: 1023-1035.
32. Chen G, Jiang M, (2011) Cyclodextrin-based inclusion complexation bridging supramolecular chemistry and macromolecular self-assembly. Chem Soc Rev 40: 2254-2266.
33. Granadero D, Bordello J, Perez-Alvite MJ, Novo M, Al-Soufi W, (2010) Host-guest complexation studied by fluorescence correlation spectroscopy: adamantane-cyclodextrin inclusion. Int J Mol Sci 11: 173-188.
34. Hanusova V, Bousova I, Skalova L, (2011) Possibilities to increase the effectiveness of doxorubicin in cancer cells killing. Drug Metab Rev 43: 540-557.
35. Kratz F, Warnecke A, (2012) Finding the optimal balance: Challenges of improving conventional cancer chemotherapy using suitable combinations with nano-sized drug delivery systems. J Control Release 164: 221-235.
36. Fan J, Fang G, Zeng F, Wang X, Wu S (2012) Water-dispersible fullerene aggregates as a targeted anticancer prodrug with both chemo- and photodynamic therapeutic actions. Small.
37. Hochdorffer K, Abu Ajaj K, Schafer-Obodozie C, Kratz F, (2012) Development of novel bisphosphonate prodrugs of doxorubicin for targeting bone metastases that are cleaved pH dependently or by cathepsin B: synthesis, cleavage properties, and binding properties to hydroxyapatite as well as bone matrix. J Med Chem 55: 7502-7515.
38. Legigan T, Clarhaut J, Renoux B, Tranoy-Opalinski I, Monvoisin A, et al. (2012) Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin. J Med Chem 55: 4516-4520.